Teerha Piratvisuth Selected Research

peginterferon alfa-2a (Pegasys)

1/2020	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
1/2019	Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
1/2019	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.
1/2018	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
6/2013	Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.
4/2009	Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
3/2008	Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
2/2008	HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
6/2005	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
9/2004	Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Teerha Piratvisuth Research Topics

Disease

37	Chronic Hepatitis B 01/2022 - 09/2004
20	Infections 01/2022 - 11/2006
13	Fibrosis (Cirrhosis) 01/2022 - 06/2008
8	Hepatocellular Carcinoma (Hepatoma) 12/2022 - 06/2012
8	Hepatitis B 01/2022 - 09/2004
4	Neoplasms (Cancer) 01/2021 - 06/2000
4	Liver Cirrhosis (Hepatic Cirrhosis) 10/2020 - 06/2000
3	Chronic Hepatitis C 03/2020 - 12/2018
3	Virus Diseases (Viral Diseases) 01/2019 - 01/2008
2	Hemorrhage 12/2021 - 12/2019
2	Sepsis (Septicemia) 01/2021 - 07/2015
2	Inflammation (Inflammations) 10/2020 - 12/2014
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022
1	Cholangiocarcinoma 05/2022
1	Acidosis 03/2022
1	Hepatic Encephalopathy 12/2021
1	Diarrhea 12/2021
1	Shock 01/2021
1	Malnutrition (Nutritional Deficiencies) 01/2021
1	HIV Infections (HIV Infection) 01/2021
1	Bone Diseases (Bone Disease) 09/2020
1	Hepatitis C 01/2020
1	COVID-19 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 12/2019
1	Hepatitis 12/2019
1	Spontaneous Abortion (Miscarriage) 03/2016
1	Congenital Abnormalities (Deformity) 03/2016
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2015
1	Liver Diseases (Liver Disease) 12/2014
1	Cross Infection (Nosocomial Infection) 07/2011
1	Liver Failure 06/2005

Drug/Important Bio-Agent (IBA)

23	Hepatitis B e AntigensIBA 01/2022 - 09/2004
18	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 06/2005
10	peginterferon alfa-2a (Pegasys)FDA Link 01/2020 - 09/2004
10	InterferonsIBA 10/2019 - 12/2009
8	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 06/2005
7	Lamivudine (Epivir)FDA Link 10/2012 - 09/2004
5	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2010
4	AntigensIBA 01/2022 - 12/2020
4	Tenofovir (Viread)FDA Link 09/2020 - 01/2010
4	Telbivudine FDA Link 03/2016 - 10/2012
3	Biomarkers (Surrogate Marker)IBA 05/2022 - 11/2011
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2022 - 12/2014
3	Alanine Transaminase (SGPT)IBA 10/2020 - 01/2010
3	SofosbuvirIBA 03/2020 - 01/2017
3	Ribavirin (Virazole)FDA LinkGeneric 03/2020 - 10/2015
3	Pharmaceutical PreparationsIBA 06/2012 - 04/2008
2	BilirubinIBA 12/2022 - 09/2020
2	AlbuminsIBA 12/2022 - 01/2015
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 05/2022 - 06/2000
2	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2020
2	Interferon-alpha (Interferon Alfa)IBA 11/2021 - 06/2005
2	velpatasvirIBA 03/2020 - 01/2019
2	sofosbuvir drug combination ledipasvirIBA 03/2020 - 01/2017
2	daclatasvirIBA 03/2020 - 01/2017
2	Vitamin D FDA LinkGeneric 04/2019 - 01/2017
2	NucleosidesIBA 01/2013 - 08/2007
2	lipoarabinomannan (LAM)IBA 10/2012 - 05/2010
2	Surface Antigens (Surface Antigen)IBA 06/2012 - 04/2009
1	Vitamin K FDA Link 05/2022
1	acarboxyprothrombin (PIVKA)IBA 05/2022
1	Prothrombin (Factor II)IBA 05/2022
1	Cytidine Triphosphate (CTP)IBA 12/2021
1	Lactulose (Duphalac)FDA LinkGeneric 12/2021
1	ABO Blood-Group SystemIBA 11/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021
1	entecavir FDA Link 09/2020
1	tenofovir alafenamideIBA 09/2020
1	Proteins (Proteins, Gene)FDA Link 03/2020
1	Capsules (Microcapsules)IBA 12/2019
1	Vitamin D-Binding ProteinIBA 04/2019
1	EnzymesIBA 01/2019
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2019
1	Iodized OilIBA 01/2019
1	A-Form DNA (A-DNA)IBA 01/2019
1	N 30IBA 01/2019
1	TabletsIBA 01/2019
1	hepatitis B hyperimmune globulinIBA 06/2017
1	Immunoglobulins (Immunoglobulin)IBA 06/2017
1	VaccinesIBA 06/2017
1	Ritonavir (Norvir)FDA Link 01/2017
1	dasabuvirIBA 01/2017
1	ombitasvirIBA 01/2017
1	paritaprevirIBA 01/2017
1	Transaminases (Aminotransferases)IBA 11/2016
1	alisporivirIBA 10/2015
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 07/2015
1	Alkaline PhosphataseIBA 12/2014
1	A-factor (Streptomyces)IBA 12/2014
1	adefovirIBA 10/2012
1	ThymalfasinIBA 06/2008
1	Immunologic Factors (Immunomodulators)IBA 06/2008
1	NucleotidesIBA 08/2007

Therapy/Procedure

25	Therapeutics 01/2022 - 09/2004
5	Liver Transplantation 01/2020 - 06/2005
4	Drug Therapy (Chemotherapy) 01/2021 - 01/2008
3	Blood Transfusion (Blood Transfusions) 07/2015 - 11/2006
2	Duration of Therapy 01/2010 - 09/2004